January 7, 2025 03:15 PM EST
FDA+

Af­ter a bump in ad­comms in 2023, FDA ad­vi­so­ry pan­els re­turned to 2022 lev­els

Max Bayer

Pharma Reporter

The FDA held 13 ad­vi­so­ry com­mit­tee pan­els last year to dis­cuss spe­cif­ic prod­uct ap­pli­ca­tions, half the to­tal in 2023 and com­pared with nine in 2022 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

No­vo ex­pands pact with Flag­ship's Va­lo to in­clude obe­si­ty, di­a­betes for $190M near-term

A service from the Financial Times